Roche strengthens oncology division by acquiring Tusk for €655m

Roche has acquired Belgian biotech Tusk Therapeutics, paid €655m. Tusk has developed its own CAR-T therapy with specific anticarcinogenic properties, which will be developed through clinical trials not sooner than 2019. Tusk was established in 2014 by Droia Oncology Ventures, which is also its main stakeholder. Roche’s shares have remained almost unaltered after the announcement.

(Source: Börsen-Zeitung)